Merck, Inc.
🇵🇭Philippines
Exercise Study in Patient With Chronic Obstructive Pulmonary Disease (0000-036)
Phase 2
Terminated
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2006-10-12
- Last Posted Date
- 2016-01-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 12
- Registration Number
- NCT00387036
Carotid IMT (Intima Media Thickening) Study (0524A-041)(TERMINATED)
Phase 3
Terminated
- Conditions
- Hypercholesterolemia, Familial
- First Posted Date
- 2006-10-06
- Last Posted Date
- 2015-09-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 937
- Registration Number
- NCT00384293
An Investigational Drug Study to Assess Weight Loss in Obese and Overweight Patients (0364-037)(TERMINATED)
- First Posted Date
- 2006-10-06
- Last Posted Date
- 2015-03-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1000
- Registration Number
- NCT00384605
Effects of Low-dose Maintenance Peg Interferon Alfa-2b Therapy Versus Supportive Care in Patients With Cirrhotic Hepatitis C With HIV (Study P04371)
Phase 3
Withdrawn
- Conditions
- Liver CirrhosisHepatitis CHIV Infections
- First Posted Date
- 2006-09-27
- Last Posted Date
- 2014-08-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT00381017
Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)
Phase 3
Completed
- Conditions
- Papillomavirus Infections
- Interventions
- Biological: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- First Posted Date
- 2006-09-26
- Last Posted Date
- 2023-05-31
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 110
- Registration Number
- NCT00380367
A 28 - 90 Days Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Injection as Empirical Therapy in Indian Adults With Persistent Fever and Neutropenia (0991-053)(COMPLETED)
Phase 3
Completed
- Conditions
- Fungal Infection
- First Posted Date
- 2006-09-25
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 50
- Registration Number
- NCT00379964
A Study to Assess the Safety, Tolerability and Efficacy of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-048)
- First Posted Date
- 2006-09-25
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 107
- Registration Number
- NCT00379951
Use of Sugammadex Administered at 5 Minutes After Administration of 1.2 mg/kg Esmeron® (19.4.205)(P05942)
- First Posted Date
- 2006-09-22
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 45
- Registration Number
- NCT00379613
Tolerability of MK0524A Versus Niacin Extended-Release (0524A-054)
Phase 3
Completed
- Conditions
- HyperlipidemiaHypercholesterolemia
- First Posted Date
- 2006-09-21
- Last Posted Date
- 2017-02-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1300
- Registration Number
- NCT00378833
Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED)
Phase 3
Completed
- Conditions
- Liver TransplantationHepatitis C, ChronicLiver Cirrhosis
- Interventions
- Drug: Combination of (a) pegylated interferon alfa-2b and (b) rebetol
- First Posted Date
- 2006-09-20
- Last Posted Date
- 2017-04-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 125
- Registration Number
- NCT00378599
© Copyright 2025. All Rights Reserved by MedPath